IPF Resources and Support
At Boehringer Ingelheim, we provide innovative treatments for Chronic Obstructive Pulmonary Disease (COPD), Idiopathic Pulmonary Fibrosis (IPF) and Asthma.
IPF is a condition of the lungs where tissue becomes thickened, stiff, and scarred over a period of time without a known cause. Research has identified key factors in the development of IPF, but no direct cause.
These key factors are:
Men are more commonly diagnosed with IPF and generally later on in life. IPF affects approximately 13 to 20 per 100,000 people worldwide.
Não foram encontrados resultados
Disclaimer
We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition, the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.
Therefore, please check the registration details of this/these product(s) locally in order to get up-to-date information.